Literature DB >> 24917466

Eleutheroside E ameliorates arthritis severity in collagen-induced arthritis mice model by suppressing inflammatory cytokine release.

Chunyan He1, Xiaohui Chen, Chunyang Zhao, Yanyan Qie, Zhaowei Yan, Xueming Zhu.   

Abstract

Rheumatoid arthritis is the most common arthritis and is mainly characterized by symmetric polyarticular joint disorders. Eleutheroside E (EE), a principal active constituent of Acanthopanax senticosus, is reported to have anti-inflammatory effect by inhibiting NF-κB activities. However, the effects of EE on rheumatoid arthritis (RA) severity are largely unknown. The purpose of this study was to indicate whether EE could ameliorate arthritis and reduce inflammatory cytokine release in collagen-induced arthritis (CIA) mice. The results showed that EE attenuated the severity of arthritis by reducing the mean arthritis score and arthritis incidence. EE also significantly decreased the inflammatory cell infiltration, pannus formation, cartilage damage, and bone erosion of CIA mice. Furthermore, EE caused a marked decrease of the production of TNF-α and IL-6 in vivo and in vitro. These observations identify a novel function of EE that results in inhibition of cytokine release, highlighting EE was a potential therapeutic agent for RA.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24917466     DOI: 10.1007/s10753-014-9880-7

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  31 in total

1.  The synthesis of Rantes, G-CSF, IL-4, IL-5, IL-6, IL-12 and IL-13 in human whole-blood cultures is modulated by an extract from Eleutherococcus senticosus L. roots.

Authors:  M W Schmolz; F Sacher; B Aicher
Journal:  Phytother Res       Date:  2001-05       Impact factor: 5.878

2.  Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.

Authors:  P E Lipsky; D M van der Heijde; E W St Clair; D E Furst; F C Breedveld; J R Kalden; J S Smolen; M Weisman; P Emery; M Feldmann; G R Harriman; R N Maini
Journal:  N Engl J Med       Date:  2000-11-30       Impact factor: 91.245

3.  The effect of Eleutheroside E on behavioral alterations in murine sleep deprivation stress model.

Authors:  Lin-Zhang Huang; Lei Wei; Hong-Fang Zhao; Bao-Kang Huang; Khalid Rahman; Lu-Ping Qin
Journal:  Eur J Pharmacol       Date:  2011-03-02       Impact factor: 4.432

4.  Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials.

Authors:  P J Charles; R J Smeenk; J De Jong; M Feldmann; R N Maini
Journal:  Arthritis Rheum       Date:  2000-11

5.  Antibodies against citrullinated proteins enhance tissue injury in experimental autoimmune arthritis.

Authors:  Kristine A Kuhn; Liudmila Kulik; Beren Tomooka; Kristin J Braschler; William P Arend; William H Robinson; V Michael Holers
Journal:  J Clin Invest       Date:  2006-04       Impact factor: 14.808

6.  Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity.

Authors:  R Madhok; A Crilly; J Watson; H A Capell
Journal:  Ann Rheum Dis       Date:  1993-03       Impact factor: 19.103

7.  Intraspecific relationship analysis by DNA markers and in vitro cytotoxic and antioxidant activity in Eleutherococcus senticosus.

Authors:  C Y Yu; S H Kim; J D Lim; M J Kim; I M Chung
Journal:  Toxicol In Vitro       Date:  2003-04       Impact factor: 3.500

8.  Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report.

Authors:  Juan J Gómez-Reino; Loreto Carmona; Vicente Rodríguez Valverde; Emilio Martín Mola; Maria Dolores Montero
Journal:  Arthritis Rheum       Date:  2003-08

Review 9.  Immunopathogenesis of collagen arthritis.

Authors:  David D Brand; Andrew H Kang; Edward F Rosloniec
Journal:  Springer Semin Immunopathol       Date:  2003-08

10.  Eleutheroside E, An Active Component of Eleutherococcus senticosus, Ameliorates Insulin Resistance in Type 2 Diabetic db/db Mice.

Authors:  Jiyun Ahn; Min Young Um; Hyunjung Lee; Chang Hwa Jung; Seok Hyun Heo; Tae Youl Ha
Journal:  Evid Based Complement Alternat Med       Date:  2013-04-10       Impact factor: 2.629

View more
  7 in total

1.  Eleutheroside E alleviates cerebral ischemia-reperfusion injury in a 5-hydroxytryptamine receptor 2C (Htr2c)-dependent manner in rats.

Authors:  Zheng Liu; Wenwei Gao; Yuanqin Xu
Journal:  Bioengineered       Date:  2022-05       Impact factor: 6.832

2.  Tea saponin additive to extract eleutheroside B and E from Eleutherococcus senticosus by ultrasonic mediation and its application in a semi-pilot scale.

Authors:  Xinyu Yang; Tingting Liu; Shuwen Qi; Huiyan Gu; Jialei Li; Lei Yang
Journal:  Ultrason Sonochem       Date:  2022-05-18       Impact factor: 9.336

3.  Inhibition of Lung Inflammation by Acanthopanax divaricatus var. Albeofructus and Its Constituents.

Authors:  Ju Hee Lee; Ya Nan Sun; Young Ho Kim; Sang Kook Lee; Hyun Pyo Kim
Journal:  Biomol Ther (Seoul)       Date:  2016-01-01       Impact factor: 4.634

4.  The Therapeutic Effect of Acanthopanax senticosus Components on Radiation-Induced Brain Injury Based on the Pharmacokinetics and Neurotransmitters.

Authors:  Chen Song; Sijia Li; Fangyuan Duan; Mengyao Liu; Shan Shan; Ting Ju; Yingchun Zhang; Weihong Lu
Journal:  Molecules       Date:  2022-02-07       Impact factor: 4.411

Review 5.  Fcγ and Complement Receptors and Complement Proteins in Neutrophil Activation in Rheumatoid Arthritis: Contribution to Pathogenesis and Progression and Modulation by Natural Products.

Authors:  Adriana Balbina Paoliello-Paschoalato; Larissa Fávaro Marchi; Micássio Fernandes de Andrade; Luciana Mariko Kabeya; Eduardo Antônio Donadi; Yara Maria Lucisano-Valim
Journal:  Evid Based Complement Alternat Med       Date:  2015-08-05       Impact factor: 2.629

Review 6.  A review on the immunomodulatory activity of Acanthopanax senticosus and its active components.

Authors:  Kit-Man Lau; Grace Gar-Lee Yue; Yuk-Yu Chan; Hin-Fai Kwok; Si Gao; Chun-Wai Wong; Clara Bik-San Lau
Journal:  Chin Med       Date:  2019-07-31       Impact factor: 5.455

7.  Combination of syringaresinol-di-O-β-D-glucoside and chlorogenic acid shows behavioral pharmacological anxiolytic activity and activation of hippocampal BDNF-TrkB signaling.

Authors:  Shouhei Miyazaki; Yoshio Fujita; Hirotaka Oikawa; Hideo Takekoshi; Hideaki Soya; Masato Ogata; Takahiko Fujikawa
Journal:  Sci Rep       Date:  2020-10-23       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.